Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Onglyza Stacks Up To Januvia, Bristol/AstraZeneca Say

Executive Summary

Merck has held a monopoly on the dipeptidyl peptidase-4 inhibitor market for type 2 diabetes since launching Januvia (sitagliptin)in 2006 - a franchise that's now approaching blockbuster status - but within the next year it could be sharing scripts with two new rivals

You may also be interested in...

Bristol Readies For Prasugrel’s Impact On Plavix, Files DPP-4 Inhibitor

Despite downplaying any concern, Bristol-Myers Squibb is preparing for a potential challenge to its blockbuster anti-clotting drug Plavix from Lilly/Daiichi Sankyo's Effient (prasugrel)

Diabetes Therapies Need Cardiovascular Safety Data For Approval, Panel Says

Sponsors of new type 2 diabetes therapies should be required to provide clinical data that can exclude an unacceptable cardiovascular risk prior to approval, FDA's Endocrinologic and Metabolic Drugs Advisory Committee concluded at a July 1-2 meeting

Takeda’s Alogliptin Strategy: Treatment Options

With five Phase III wins for type 2 diabetes, company plans to build on Actos’ success.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts